Mutation of PIK3CA: Possible risk factor for cervical carcinogenesis in older women

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 409-416

  Cui, Baoxia ^a,b   Zheng, Biying ^a,c   Zhang, Xi ^a,b   Stendahl, Ulf ^d   Andersson, Sonia ^a   Wallin, Keng Ling ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SHANDONG UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cervical carcinoma; Cervical intraepithelial neoplasia; Human papillomaviruses; Mutation; PIK3CA

Indexed keywords

CYSTEINE; GENOMIC DNA; GLYCINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN PIK3CA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UTERINE CERVIX CARCINOMA;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGED; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 64549095616     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000164     Document Type: Article

References (35)

1. Saraiya M, Ahmed F, Krishnan S, Richards TB, Unger ER and Lawson HW: Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol 109: 360-370, 2007. Erratum in: Obstet Gynecol 109: 1002, 2007.
2. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ and Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003.
3. Wallin KL, Wiklund F, Angstrom T, Bergman F, Stendahl U, Wadell G, Hallmans G and Dillner J: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 341: 1633-1638, 1999.
4. Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC and Burk RD: Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 191: 1796-1807, 2005.
5. Ferreccio C, Prado RB, Luzoro AV, Ampuero SL, Snijders PJ, Meijer CJ, Vaccarella SV, Jara AT, Puschel KI, Robles SC, Herrero R, Franceschi SF and Ojeda JM: Population-based prevalence and age distribution of human papillomavirus among women in Santiago, Chile. Cancer Epidemiol Biomarkers Prev 13: 2271-2276, 2004.
6. Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, Sargent A and Peto J: ARTISTIC Trial Study Group: HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95: 56-61, 2006.
7. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao YL, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Meijer CJ and Munoz N: Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 119: 2677-2684, 2006.
8. Munger K and Howley PM: Human papillomavirus immortalization and transformation functions. Virus Res 89: 213-228, 2002.
9. Coffer PJ, Jin J and Woodgett JR: Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J 335: 1-13, 1998.
10. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
11. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002.
12. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004.
13. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, Herrero A, Fusco A, Cameselle-Teijeiro J and Santoro M: Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65: 10199-10207, 2005.
14. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S, Trink B and Sidransky D: Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7: R609-R616, 2005.
15. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI and Boyd J: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11: 2875-2878, 2005.
16. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP and Su GH: PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 12: 1441-1446, 2006.
17. Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, Asaoka Y, Matsumura M, Kawabe T and Omata M: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65: 4562-4567, 2005.
18. Bader AG, Kang S and Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 103: 1475-1479, 2006.
19. Karakas B, Bachman KE and Park BH: Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94: 455-459, 2006.
20. Wu G, Mambo E, Guo Z, Hu S, Huang X, Gollin SM, Trink B, Ladenson PW, Sidransky D and Xing M: Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab 90: 4688-4693, 2005.
21. Li SY, Rong M, Grieu F and Iacopetta B: PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96: 91-95, 2006.
22. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK and Shen CY: PIK3CA as an oncogene in cervical cancer. Oncogene 19: 2739-2744, 2000.
23. Bertelsen BI, Steine SJ, Sandvei R, Molven A and Laerum OD: Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer 118: 1877-1883, 2006.
24. Chua KL, Wiklund F, Lenner P, Angstrom T, Hallmans G, Bergman F, Sapp M, Schiller J, Wadell G, Hjerpe A and Dillner J: A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 68: 54-59, 1996.
25. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C and Wilander E: The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 37: 246-250, 2001.
26. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE and Park BH: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775, 2004.
27. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A and Parsons R: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559, 2005.
28. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB and Phillips WA: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681, 2004.
29. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ and Lee SH: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24: 1477-1480, 2005.
30. Oda K, Stokoe D, Taketani Y and McCormick F: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673, 2005.
31. Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A, Tardon A, Serra C and Real FX: PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66: 7401-7404, 2006.
32. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M and Fujii Y: PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54: 209-215, 2006.
33. Kozaki K, Imoto I, Pimkhaokham A, Hasegawa S, Tsuda H, Omura K and Inazawa J: PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 97: 1351-1358, 2006.
34. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ and Ellenson LH: PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12: 5932-5935, 2006.
35. Buttitta F, Felicioni L, Barassi F, Martella C, Paolizzi D, Fresu G, Salvatore S, Cuccurullo F, Mezzetti A, Campani D and Marchetti A: PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 208: 350-355, 2006.